Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Beam Therapeutics Inc (BEAM)

$26.02 -0.27 (-1.03%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	2.70B
Revenue (ttm)	139.74M
Net Income (ttm)	-79.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-57.24%
Debt to Equity Ratio	0.09

Volume	1,577,500
Avg Vol	2,312,042
Day's Range	N/A - N/A
Shares Out	102.88M
Stochastic %K	35%
Beta	2.18
Analysts	Strong Sell
Price Target	$50.40

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304,...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8775

Website: beamtx.com

Address:

238 Main Street, Cambridge, United States

Austinhilton Jul. 29 at 5:50 PM

$NOW looking to reclaim key EMAs as momentum picks up 👀 $BEAM $AVGO $BETR

0 · Reply

smithwaldJR Jul. 27 at 10:01 PM

$BEAM

0 · Reply

darioras Jul. 27 at 9:49 AM

$BEAM To me was a good entrance already at $26.. I made already quite a lot of money so far trading this stock

0 · Reply

StockBillionaire2112 Jul. 26 at 5:16 AM

$BEAM what is a good entry price here? $22 ?

0 · Reply

GSTX7 Jul. 23 at 8:14 PM

$BEAM

0 · Reply

Arcides Jul. 20 at 10:49 PM

$BEAM $CRSP those 2 shits ares untouchables...

1 · Reply

jewell69 Jul. 20 at 6:32 PM

$BEAM RE-Entry 7/20/2026 Buy BEAM BEAM THERAPEUTICS INC 200 $26.50 -$5,300.00 More 05/06/2026 Sell BEAM BEAM THERAPEUTICS INC 129 $29.84 $0.11 $3,849.25 More 05/05/2026 Buy BEAM BEAM THERAPEUTICS INC 50 $28.74 -$1,437.00 More 05/05/2026 Buy BEAM BEAM THERAPEUTICS INC 79 $29.10 -$2,298.90

0 · Reply

Auto_MA_T_Ka Jul. 19 at 9:01 PM

Beam Therapeutics $BEAM is back to its weekly moving average support.

0 · Reply

darioras Jul. 19 at 11:19 AM

$BEAM Ready for the next climb up?

0 · Reply

Zeestallion Jul. 17 at 7:18 PM

$VIVS just waiting to see when the market sees what I see. Top pharmaceutical company Eil Lilly. TRILLION DOLLAR company invested into this.$BEAM $PACB $JSPR $VRTX

2 · Reply

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

2026-07-08T16:45:10.000Z - 21 days ago

TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647

PRME

2026-07-08T15:45:15.000Z - 21 days ago

Resolution in favor of Prime has limited impact to Beam, says BofA

PRME

2026-07-08T15:40:10.000Z - 21 days ago

Prime Medicine reports positive resolution to arbitration with Beam Therapeutics

PRME

2026-06-18T11:05:09.000Z - 5 weeks ago

Beam Therapeutics announces U.S. FDA clearned IND application for BEAM-304

Jun 18, 2026, 7:00 AM EDT - 5 weeks ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

Jun 17, 2026, 12:30 PM EDT - 6 weeks ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Jun 3, 2026, 10:30 AM EDT - 2 months ago

Beam Therapeutics Transcript: AGM 2026

May 20, 2026, 10:30 AM EDT - 2 months ago

Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-18T20:35:07.000Z - 2 months ago

Beam Therapeutics presents Phase 1/2 data for BEAM-302

May 18, 2026, 4:00 PM EDT - 2 months ago

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

May 13, 2026, 11:49 AM EDT - 2 months ago

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

May 13, 2026, 7:00 AM EDT - 2 months ago

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

2026-05-13T10:37:27.000Z - 2 months ago

Beam Therapeutics price target lowered to $39 from $40 at Bernstein

May 12, 2026, 9:30 AM EDT - 2 months ago

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

2026-05-07T13:39:55.000Z - 2 months ago

Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)

May 7, 2026, 7:00 AM EDT - 2 months ago

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 7, 2026, 7:00 AM EDT - 2 months ago

Beam Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Beam Therapeutics Quarterly report: Q1 2026

2026-04-27T16:07:48.000Z - 3 months ago

Beam Therapeutics rises 10.7%

2026-04-27T14:34:03.000Z - 3 months ago

Beam Therapeutics rises 10.8%

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Beam Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Beam Therapeutics Proxy statement: Proxy filing

2026-04-01T21:20:15.000Z - 4 months ago

Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial

Apr 1, 2026, 5:12 PM EDT - 4 months ago

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

2026-03-26T10:25:10.000Z - 4 months ago

Beam Therapeutics price target raised to $68 from $64 at Citi

2026-03-25T16:55:13.000Z - 4 months ago

Clear Street sees buying opportunity for Beam Therapeutics after study update

Mar 25, 2026, 8:00 AM EDT - 4 months ago

Beam Therapeutics Transcript: Study result

Mar 25, 2026, 8:00 AM EDT - 4 months ago

Beam Therapeutics Press release: Study result

Mar 25, 2026, 8:00 AM EDT - 4 months ago

Beam Therapeutics Slides: Study result

2026-03-25T11:27:05.000Z - 4 months ago

Beam Therapeutics announces safety, efficacy data from BEAM-302 trial

Mar 25, 2026, 7:00 AM EDT - 4 months ago

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

2026-02-25T14:29:20.000Z - 5 months ago

Beam Therapeutics price target raised to $26 from $22 at RBC Capital

2026-02-25T13:38:56.000Z - 5 months ago

Beam Therapeutics price target raised to $65 from $57 at Wedbush

2026-02-25T11:54:44.000Z - 5 months ago

Beam Therapeutics price target raised to $75 from $74 at Canaccord

Feb 24, 2026, 8:00 AM EST - 5 months ago

Beam Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 5 months ago

Beam Therapeutics Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 5 months ago

Beam Therapeutics Earnings release: Q4 2025

Feb 24, 2026, 7:01 AM EST - 5 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Feb 24, 2026, 7:00 AM EST - 5 months ago

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Feb 23, 2026, 4:00 PM EST - 5 months ago

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Jan 13, 2026, 8:15 PM EST - 7 months ago

Beam Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 7 months ago

Beam Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 5:00 PM EST - 7 months ago

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Dec 18, 2025, 4:01 PM EST - 7 months ago

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 8:00 AM EST - 8 months ago

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Nov 19, 2025, 10:30 AM EST - 9 months ago

Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Nov 4, 2025, 4:00 PM EST - 9 months ago

Beam Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 9 months ago

Beam Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 7:00 AM EST - 9 months ago

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 3, 2025, 9:00 AM EST - 9 months ago

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Sep 8, 2025, 10:30 AM EDT - 11 months ago

Beam Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 1:30 PM EDT - 11 months ago

Beam Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 4:00 PM EDT - 11 months ago

Beam Therapeutics Transcript: Citi's Biopharma Back to School Conference

Aug 25, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Quarterly report: Q2 2025

Jun 13, 2025, 4:00 PM EDT - 1 year ago

Beam Therapeutics Transcript: The European Hematology Association Congress 2025

Jun 13, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

May 29, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 20, 2025, 11:00 AM EDT - 1 year ago

Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 9:30 AM EDT - 1 year ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Quarterly report: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Earnings release: Q1 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Proxy statement: Proxy Filing

Apr 5, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 1 year ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 11, 2025, 3:30 PM EDT - 1 year ago

Beam Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 10, 2025, 1:40 PM EDT - 1 year ago

Beam Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Transcript: Study Update

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Press release: Study Update

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Slides: Study Update

Mar 10, 2025, 6:01 AM EDT - 1 year ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 1 year ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Mar 3, 2025, 1:50 PM EST - 1 year ago

Beam Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Annual report: Q4 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Earnings release: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Feb 6, 2025, 2:30 PM EST - 1 year ago

Beam Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 4:30 PM EST - 1 year ago

Beam Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Transcript: Status Update

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Press release: Status Update

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Slides: Status Update

Dec 8, 2024, 1:45 PM EST - 1 year ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 19, 2024, 5:00 AM EST - 1 year ago

Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Beam Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Beam Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Jul 15, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Jun 26, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 14, 2024, 3:00 AM EDT - 2 years ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Austinhilton Jul. 29 at 5:50 PM

$NOW looking to reclaim key EMAs as momentum picks up 👀 $BEAM $AVGO $BETR

0 · Reply

smithwaldJR Jul. 27 at 10:01 PM

$BEAM

0 · Reply

darioras Jul. 27 at 9:49 AM

$BEAM To me was a good entrance already at $26.. I made already quite a lot of money so far trading this stock

0 · Reply

StockBillionaire2112 Jul. 26 at 5:16 AM

$BEAM what is a good entry price here? $22 ?

0 · Reply

GSTX7 Jul. 23 at 8:14 PM

$BEAM

0 · Reply

Arcides Jul. 20 at 10:49 PM

$BEAM $CRSP those 2 shits ares untouchables...

1 · Reply

jewell69 Jul. 20 at 6:32 PM

0 · Reply

Auto_MA_T_Ka Jul. 19 at 9:01 PM

Beam Therapeutics $BEAM is back to its weekly moving average support.

0 · Reply

darioras Jul. 19 at 11:19 AM

$BEAM Ready for the next climb up?

0 · Reply

Zeestallion Jul. 17 at 7:18 PM

$VIVS just waiting to see when the market sees what I see. Top pharmaceutical company Eil Lilly. TRILLION DOLLAR company invested into this.$BEAM $PACB $JSPR $VRTX

2 · Reply

TheWolfOfWaterdown Jul. 16 at 7:21 PM

$NTLA $CRSP $PRME $BEAM Whole gene editing sector getting butchered this week Hopefully support is held and can slowly recover

0 · Reply

PorkchopSquats Jul. 16 at 4:30 PM

$ARKG I’m just trying to find a silver lining here, this shit sucks lmfao. @Thelonius_Stonk hopium confirmation plz. $CRSP $NTLA $PRME $BEAM

2 · Reply

ATTAB0Y Jul. 15 at 2:37 PM

$PRME $BEAM https://www.statnews.com/2026/07/09/arpa-h-160-million-custom-gene-editing-funding-rare-disease/ ARPA-H, the U.S. Government “moonshot” agency for health research, announced Thursday that it will spend up to $160 million to push forward custom gene editing treatments for a spate of rare diseases.

1 · Reply

howardlindzon Jul. 13 at 3:56 PM

$BEAM

0 · Reply

Windytimes Jul. 13 at 1:42 PM

$CRBU $PRME $BEAM $NTLA $CRSP MADDENING!!!!

1 · Reply

RotationReport Jul. 13 at 12:07 PM

$BEAM got stopped out of this thing Friday. gene editing stocks largely flushed to the 50 days, could rip from here- but whatever. whenever a trade starts green and goes red, especially given this market backdrop - protecting capital is #1

4 · Reply

Auto_MA_T_Ka Jul. 12 at 8:02 PM

Beam Therapeutics $BEAM can't close above its descending weekly moving average resistance band. The ascending MA support cluster closes in from below.

0 · Reply